The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. by Valenti MT et al.
RESEARCH ARTICLE Open Access
The effect of risedronate on osteogenic lineage is
mediated by cyclooxygenase-2 gene upregulation
Maria Teresa Valenti1, Sandro Giannini2, Luca Donatelli1, Mirko Zanatta1, Francesco Bertoldo1, Stefania Sella2,
Maria Teresa Vilei2, Elena Ossi2, Giuseppe Realdi2, Vincenzo Lo Cascio1, Luca Dalle Carbonare1*
Abstract
Introduction: The purpose of this study was to evaluate the effects of risedronate (Ris) in the modulation of bone
formation in rats with glucocorticoid (GC)-induced osteoporosis by histomorphometric, immunohistochemical and
gene expression analyses.
Methods: We analyzed structure, turnover and microarchitecture, cyclooxygenase 2 (COX-2) levels and osteocyte
apoptosis in 40 female rats divided as follows: 1) vehicle of methylprednisolone (vGC) + vehicle of risedronate
(vRis); 2) Ris 5 μg/Kg + vGC; 3) methylprednisolone (GC) 7 mg/Kg + vRis; 4) GC 7 mg/Kg +Ris 5 μg/Kg. In addition,
we evaluated cell proliferation and expression of COX-2 and bone alkaline phosphatase (b-ALP) genes in bone
marrow cells and MLO-y4 osteocytes treated with Ris alone or in co-treatment with the selective COX-2 inhibitor
NS-398 or with dexametasone.
Results: Ris reduced apoptosis induced by GC of osteocytes (41% vs 86%, P < 0.0001) and increased COX-2
expression with respect to controls (Immuno-Hystochemical Score (IHS): 8.75 vs 1.00, P < 0.0001). These positive
effects of Ris in bone formation were confirmed by in vitro data as the viability and expression of b-ALP gene in
bone marrow cells resulted increased in a dose dependent manner.
Conclusions: These findings suggest a positive effect of Ris in bone formation and support the hypothesis that the
up-regulation of COX-2 could be an additional mechanism of anabolic effect of Ris.
Introduction
Bisphosphonates (BPs), synthetic analogs of pyropho-
sphate, are the most effective inhibitors of bone resorp-
tion and are currently used in the treatment of several
bone diseases. Their mechanism of action has been well
described. They bind tightly to bone mineral surface,
penetrate into osteoclasts and stimulate their apoptosis
through the inhibition of the mevalonate pathway [1].
Recent findings suggest that bisphosphonates may also
indirectly suppress bone resorption through their action
on osteoblasts [2], and osteocytes [3], which could
represent another target for these drugs.
Instead, it is not clear if BPs have also a beneficial
influence on the bone formation process. Histomorpho-
metric analysis in osteoporotic subjects indicates that
BPs may increase the mean wall thickness and reduce
the imbalance between formation and resorption at the
basic multicellular unit (BMU) [4,5], leading to a conti-
nuing increase in bone mineral density (BMD) even
after a long period of treatment, as demonstrated in
clinical studies [6].
They also control osteoblastic proliferation and differ-
entiation [7,8], modulate osteoblast production of extra-
cellular matrix proteins, regulate the secretion of several
cytokines and growth factors [9,10] and enhance prolif-
eration and maturation of bone marrow stromal cells to
osteoblastic lineage [11]. Bisphosphonates are also able
to prevent apoptosis of osteoblasts and osteocytes
induced by glucocorticoid therapy [12]. It is well known
that osteocytes are well differentiated osteoblasts regu-
larly spaced throughout the mineralized matrix. They
are believed to detect bone microdamage and to trans-
mit signals leading to its repair [13,14].
The disruption of the osteocyte network could com-
promise this mechanism, leading to accumulated micro-
damage and increased bone fragility. Such a defect in
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bone quality could account for the higher incidence of
fractures and the disproportion between the significant
increase in bone fragility and the relative small decrease
of BMD observed, for example, in glucocorticoid
induced osteoporosis [12,15].
In our previous histomorphometric study on glucocor-
ticoid-induced osteoporosis [16] we found that rats trea-
ted with risedronate (Ris) showed increased trabecular
number and thickness and decreased trabecular separa-
tion not only with respect to glucocorticoid treated rats
but also with respect to controls. In addition, increased
wall thickness, the end product of osteoblastic activity,
was observed. In terms of turnover, rats treated with Ris
showed a reduced activation frequency with an
increased active Formation Period. All these findings
suggest an effect of Ris on osteoblastic lineage and sup-
port the hypothesis of a neoformative activity of
bisphosphonates.
The mechanism by which bisphosphonates stimulate
osteoblasts is not yet completely elucidated. Giuliani
et al. [10] reported that the anabolic effect of BPs was
associated with the stimulation of b-FGF, while Mundy
et al. demonstrated that the anabolic effect of statins,
which influence the mevalonate pathway as BPs, was
due to their stimulation of Bone Morphogenetic Pro-
tein-2 (BMP-2) [17]; BMP-2 gene expression was also
upregulated during osteoblast maturation after BP treat-
ment [18]. Von Knoch et al. showed that a cascade of
osteoblast-related genes including BMP-2, cbfa-1, type 1
collagen and Bone Sialo-Proteins (BSP) were up regu-
lated and significantly increased in bone marrow stromal
cells after BP treatment [11]. The Osteoprotegerin/
Receptor Activator of Nuclear Factor-B Ligand (OPG/
RANKL) system is also influenced by BPs and may be
related, at least in part, to the stimulatory effects of BPs
on osteoblastic differentiation [2].
In addition, it has been shown that exogenous and
endogenous prostaglandins (PGs) modulate both bone
formation and resorption [19-23]. PGs are produced by
cyclooxygenase (COX), which is a rate-limiting enzyme
that converts arachidonic acid to PGs [24]. Three iso-
forms of COX are recognized: COX 1, which is consti-
tutively expressed, COX-2, which is inducible by
multiple factors and involved in PGs production during
inflammation and other acute responses [25] and COX-
3, which has recently been related to paracetamol-
induced hypothermia and analgesia [26,27]. On the con-
trary, the inhibition of cyclooxygenase (COX) has been
associated with decreased bone formation in vivo [28]
and delayed experimental fracture healing [29].
Strontium ranelate, a new treatment for postmeno-
pausal osteoporosis that exerts both antiresorptive and
anabolic effects on bone, is able to influence prosta-
glandins metabolism. Strontium ranelate induces
COX-2 expression and promotes PGE2 production
and activity in murine primary calvarian osteoblast
trough ERK pathway [30]. It also increases osteoblastic
differentiation and mineralization, acting on early
osteoblastic precursors to induce COX-2 and PGE2
production [31].
Up to now, studies about the effects of BPs on
cyclooxygenase are lacking. On the basis of these data,
we hypothesized that BPs could upregulate COX-2
expression according to their putative anabolic effect on
bone previously suggested by histomorphometric results.
To verify this hypothesis, we studied the effect of Ris by
evaluating histomorphometric parameters in rat tibiae
and apoptosis and COX-2 expression in femur speci-
mens in the presence or absence of a negative effect on
osteoblastic/osteocytic lineage induced by glucocorti-
coids. To verify the presence of a direct stimulus of Ris
on osteoblastic cells, we analysed in vitro the viability
and COX-2 gene expression in bone marrow stromal
cells treated with Ris at different concentrations, in the
presence and absence of NS-398, a selective COX-2
inhibitor [32]. In addition, to analyze the effects of
bisphosphonates on osteogenic differentiation, we evalu-
ated the mRNA expression of bone marker Alkaline
Phosphatase (b-ALP) on stromal cells treated with Ris at
different concentrations. On the same model, we investi-
gated a possible relationship between COX-2 pathway
and osteogenic differentiation by analyzing mRNA
b-ALP expression in presence or absence of COX-2
inhibitor.
Materials and methods
Animals
Forty six-month-old female Sprague-Dawley rats of
approximately 200 to 300 g body weight were obtained
from Charles River Italia (Calco, Italy). All rats were
housed under similar conditions. They were fed a stan-
dard rodent diet containing 0.97% calcium, 0.85% phos-
phorus, 1,045 IU/Kg vitamin D3, 22.5% protein, 5.5%
fat, 52% carbohydrate, and were given access to tap
water ad libitum.
The animal procedures were approved by the local
government authorities and were conducted in accord
with accepted standards of humane animal care, as out-
lined in the Ethical Guidelines.
Drugs
Risedronate (Ris) in powder form was provided by Proc-
ter and Gamble Pharmaceuticals Inc. (Cincinnati, OH,
USA). Ris was dissolved in deionized water and was
administered at 5 μg/Kg subcutaneously (s.c.) three
times a week. Methylprednisolone (GC, Solu-Medrol -
Pharmacia, Stockholm, Sweden)) was diluted in a
sesame oil vehicle at a concentration of 7 mg/kg.
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Study protocol in vivo
At the beginning of the study, rats were randomly
divided into four groups (10 rats each) and treated s.c.
three times a week as follows:
1. Control group: GC vehicle (vGC) + Ris vehicle
(vRis);
2. Ris group: Ris 5 μg/Kg body weight + vGC;
3. GC Group: GC 7 mg/Kg + vRis;
4. GC + Ris Group: GC 7 mg/Kg and Ris 5 μg/Kg.
The rats were weighed once a week to adjust the drug
dose to body weight. The study’s experimental period
lasted 30 days. To evaluate dynamic parameters of bone
formation, the rats received double fluorochrome label-
ing with demeclocycline, 25 mg/Kg s.c. on Day -14 and
-13, and with calcein, 10 mg/Kg s.c. on Day -4 and -3
prior to sacrifice.
Histomorphometry
The right tibiae were removed, dissected free of soft tis-
sue, and fixed in 70% reagent alcohol. The samples were
embedded undecalcified in methyl-methacrylate resin
(Merck 800590, Darmstadt, Germany).
Measurements were performed by means of an image
analysis system consisting of an epifluorescent micro-
scope (Leica DMR, Leica Microsystems, Wetzlar, Ger-
many) connected to an analogic 3 CCD camera (Sony
DXC 390P; Sony, Tokio, Japan) and a computer
equipped with a specific software for histomorphometric
analyses (Bone, Explora Nova, La Rochelle, France). The
area analyzed was restricted to the trabecular bone of
the secondary spongiosa area between 2 and 4 mm dis-
tal to the growth plate-metaphyseal junction [33].
Histomorphometric parameters are reported in accor-
dance with the ASBMR Committee nomenclature [34].
Thickness results were adjusted for the obliquity of
sections by multiplying by π/4 [34].
Immunohistochemical determination of COX-2 expression
Explants of left femora were fixed in 4% buffer formalin
for 24 hours, decalcified with 0.5 mol/L ethylendiaminete-
traacetic acid, pH 8, for 7 to 10 days, paraffin embedded,
and cross sectioned (5 μm thick) at three different levels.
Goat Serum was purchased from Sigma-Aldrich Co. (St.
Louis, MO, USA); Primary Antibody, rabbit anti-mouse
cox-2, from NeoMarkers Inc. (Fremont, CA, USA); Sec-
ondary Antibody, goat anti-rabbit IgG-B, from SantaCruz
Biotechnology Inc., Santa Cruz, CA, USA; ABC solution,
Vectastain ABC kit, from Vector Laboratories Inc. (Burlin-
game, CA, USA); DAB solution, Liquid DAB Substrate
Chromogen System, from DakoCytomation (Fort Collins,
Colorado, USA). Immunohystochemistry was performed
on paraffin-embebbed specimen sections, following the
technique of Fortier et al. [35], with the same modifica-
tion. Briefly, slides were stored in the stove at 60°C till
paraffin loosed, and then were washed in xylene, followed
by rehydration through graded ethanol washes. Permeabi-
lization was performed by heating at 70° in a humidified
chamber, the sections were previously covered with
10 mM citrate buffer, pH 6.0, followed by cooling at room
temperature. The endogenous peroxidases were blocked
by incubation in DI water 0.3% H2O2, and non-specific
binding was prevented by incubation in PBS 10% Goat
Serum. The first antibody (rabbit anti-mouse COX-2) was
diluted 1:25 in PBS 10% Goat Serum, and the slides were
incubated overnight at 4°C in humidified chamber. Slides
were then washed in 1% Triton PBS, following a second
blocking step with PBS 10% Goat Serum. Secondary bioti-
nylated antibody (goat anti-rabbit IgG-B) was added at the
dilution of 1:100. After 30 minutes of incubation at room
temperature, sections were washed in PBS 1% Triton
X-100 followed by only PBS, before staining by use of a
Vectastain peroxidise standard ABC kit, and DAB solu-
tion, both according to the suppliers’ protocol. Cells were
then counterstained with haematoxylin and mounted with
glycerol solution. For each sample, six random fields at
40 × of magnification were analyzed by counting positive
cells with respect to total cells. Results were expressed as
an immunohistochemical score (IHS), based on the
German Immunoreactive Score, which combines quantity
and intensity values. The IHS is calculated by combining
the percentage of immunoreactive cells (quantity score, %)
with an estimate of the staining intensity; quantity score:
no staining is scored as 0; 1 to 10% of cells stained scored
as 1; 11 to 50% as 2; 51 to 80% as 3; and 81 to 100% as 4;
staining intensity was rated on a scale of from 0 to 3, with
0 being negative, 1 weak, 2 moderate, and 3 strong. The
raw data were converted to IHS by multiplying the quan-
tity and staining intensive score.
Apoptosis
Apoptotic nuclei in paraffined tissue were identified by
Terminal deoxynucleotidyl Transferase-Biotin-dUTP
nick end labeling (TUNEL) technique. The procedure
was the one reported in the manufacturer’s instruction
(Roche, Mannheim, Germany). Apoptotic nuclei were
identified by the red precipitate obtained by incubating
the glass slides with 0.04% 3-amino-9-ethyl- carbazole
(AEC) in 50 mM sodium citrate buffer, pH 5 containing
0.015% H2O2. The values were expressed as the percen-
tage of TUNEL-position nuclei with respect to the total
haematoxylin-stained nuclei. Six different fields with
about 40 total cells for each sample were measured.
Study protocol in vitro
Cell culture
b-glycero-phosphate, 0.1 mM L-ascorbic 2-phosphate
and dexametasone were purchased from StemCell
(StemCell Technologies, Vancouver, BC, Canada).
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Almost all other chemicals were from Sigma (St Louis,
MO, USA). Other companies are specified in the text.
Bone marrow cells were obtained from 8 to 10 week-
old Sprague-Dawley rats. The femurs were removed
aseptically and dissected, the ends of bones were cut
and the marrow was flushed out with DMEM by using a
needle and syringe. The marrow was disperded gently by
pipetting several times to obtain a single cell suspension
and the cells were counted with a hemocytometer. Cells
were seeded into 25 ml cell culture flasks at a density of
1 × 106 cells/ml and culture for 48 h at 37°C in a humi-
dified atmosphere with 5% CO2 in DMEM containing
2 mM L glutamine, 20% fetal bovine serum, 100 U/ml
streptomycin and 100 μg/ml penicillin. After 48 h, all
nonadherent cells were removed and the adherent cells
were grown for an additional period. At sub-confluence,
cells were detached with trypsin and at the third passage
the cells were plated in a 96-well cell culture plate or
25 ml cell culture flasks at a density of 3.0 × 105 cells/
ml. The cells were cultured in osteogenic differentiation
medium consisting of DMEM with 10% FBS supplemen-
ted with 10 mM b-glycero-phosphate and 0.1 mM
L-ascorbic 2-phosphate.
MLO-Y4 osteocytes, a cell line derived from mouse
long bones (provided by Dr. L. F. Bonewald, University
of Missouri, Kansas City, MO [36]), was cultured in -
minimum essential medium (-MEM) supplemented with
2.5% fetal bovine serum (FBS; Gibco, Grand Island, NY,
USA), 2.5% calf serum (Gibco), 100 U/ml streptomycin
and 100 μg/ml penicillin at 37°C and 5% CO2 in air.
The cells were cultured in osteogenic differentiation
medium consisting of -MEM with 2.5% fetal bovine
serum, 2.5% calf serum, 100 U/ml streptomycin and
100 μg/ml penicillin supplemented with 10 mM b-
glycero-phosphate and 0.1 mM L-ascorbic 2-phosphate.
The cultures were treated with Ris at concentrations
ranging from 0.1 to 10 μM with or without NS-398 (0.1
μM), or with dexametasone (1 μM) as specified in the
figures, and controls were treated with vehicle (DMSO,
< 0.1%).
XTT assay
Cell viability was evaluated by a colorimetric assay based
on the reduction of the tetrazolium salt XTT [(sodium
3I-(1-phenylamino-carbonyl-3,4-tetrazolium)-bis(4-meth-
oxy-6-nitro)] benzene sulfonic acid hydrate) by mito-
chondrial dehydrogenase of viable cells to a formazan
dye (Cell proliferation kit II – XTT Roche). Briefly, cells
were cultivated in 96 microtitre plates in medium con-
taining different concentrations of Ris with or without
NS-398. After 72 h, 50 μl XTT labeling mixture was
added to each well and incubated at 37°C for 4 h. The
spectrophotometric absorbance of the samples was mea-
sured using a microtitre plate (ELISA) reader at a wave-
length of 450 nm.
Total RNA extraction and reverse transcription
Total RNA was extracted from each cell pellet using
the RNAeasy minikit (Qiagen, Duesseldorf, Germany)
with DNAse I treatment. The amount and purity of
the RNA were checked by measuring the absorbance
at 260 and 280 nm, and where a ratio ranging from
1.8 to 2.0 was taken to be pure. First-strand cDNA
was generated from 1 μg of total RNA using the First
Strand cDNA Synthesis Kit (GE Healthcare, Buckin-
ghamshire, United Kingdom), with random hexamers,
(GE Healthcare) according to the manufacturer’s pro-
tocol. RT product was aliquoted in equal volumes and
stored at -80°C.
Real time RT-PCR
mRNA quantification was analyzed by Relative Standard
Curve Method (Chemistry guide Applied Biosystems
(Foster City, CA, USA). PCR was performed in a total
volume of 25 μl containing 1 × Taqman Universal PCR
Master mix, no AmpErase UNG and 5 μl of cDNA from
each sample; pre-designed, Gene-specific primers and
probe sets for each gene were obtained from Assay-on-
Demande Gene Expression Products (Rat (RN01483828-
m1, Cox2; RN01516028-m1, b-ALP; RN00667869-m1,
ACTb) (mouse (Mm01307329-m1, Cox2; Mm01187117-
m1, b-ALP; ACTb human) Applied Biosystems). The
Real Time amplifications included 10 minutes at 95°C
(AmpliTaq Gold activation), followed by 40 cycles at 95°
C for 15 seconds and at 60°C for 1 minute. Thermocy-
cling and signal detection were performed with ABI
Prism 7300 Sequence Detector (Applied Biosystems).
Signals were detected according to the manufacturer’s
instructions and we selected the ΔRn in the exponential
phase of amplification plots to determine the Ct values
and to obtain the linearity of calibration curves.
PCR efficiencies were calculated with a relative stan-
dard curve derived from a four cDNA dilution series in
triplicate and gave regression coefficients greater than
0.98 and efficiencies greater than 96%. To normalize
gene expression we amplified the housekeeping gene
ACTb. The gene expression levels were calculated for
each sample in triplicate after normalization against the
housekeeping gene (ACTb), using the relative fold
expression differences [37].
Statistical analysis
Results were expressed as means ± SD. The statistical
analysis was assessed by one way and two way analysis
of variance (ANOVA). In all analyses, a P-value less
than 0.05 (P < 0.05) was considered a significant differ-
ence. Differences among groups yielding a statistical sig-
nificance with P < 0.05 were tested with Bonferroni as a
post-hoc test. Statistical analyses were performed by
using SPSS for Windows version 16.0 (SPSS Inc.,
Chicago, IL, USA).
Valenti et al. Arthritis Research & Therapy 2010, 12:R163
http://arthritis-research.com/content/12/4/R163
Page 4 of 13
Results
In vivo study
Histomorphometric effects of risedronate
BV/TV was higher in Ris treated groups with respect to
GC and control groups. Accordingly, Ris-treated group
showed higher Trabecular Thickness and Number and
lower Trabecular Separation than GC and control
groups (Table 1). In addition, Ris treated groups showed
increased Wall Thickness, the end product of osteoblas-
tic activity. As for turnover, we observed decreased Acti-
vation Frequency in Ris treated rats, confirming our
previous findings [16].
Effects of risedronate and glucocorticoids on osteocytic
apoptosis
According to Plotkin et al. [12], rats treated with GC
showed a significant increase of apoptosis with respect
to controls (86.4 vs 10.2%, P < 0.001, Figure 1), reduced
by the addition of Ris.
Effects of risedronate and glucocorticoids on osteocytic
COX-2 expression
We evaluated COX-2 expression in all rats. Rats treated
with Ris showed an increased expression of osteocytic
COX-2 vs placebo group (IHS: 7.8 vs 0.6, P < 0.001, Fig-
ure 2). On the contrary, rats treated with GC did not
show any significant difference in COX-2 expression
with respect to placebo.
On the other hand, the combined treatment (GC and
Ris) induced a significant increase of COX-2 expression
with respect to the placebo (IHS: 4.8 vs 0.6, P < 0.001),
even if significantly lower than Ris alone treated group
(IHS: 4.8 vs 7.8, P < 0.001). Furthermore, increased
COX-2 gene expression observed with Ris was main-
tained even in the presence of GC, suggesting that Ris
counteracts negative effects of GC on osteoblastic
lineage.
In vitro study
Effects of risedronate on cell viability
We evaluated, using bone marrow stromal cells and
MLO-y4 osteocytes, the effect of Ris at concentrations
of 0, 0.1 to 10 μM with or without COX-2 inhibitor NS-
398 (0.1 μM) after three days of culture. The increased
levels of cell viability obtained by XTT test at different
concentrations of Ris are reported in Figure 3a. This
effect could be associated with an increased proliferation
and/or survival of cells. Nevertheless, when we inhibited
the COX-2 pathway using NS-398, the effect of Ris on
cell viability was significantly reduced, at least at the
highest concentrations. We also evaluated cell viability
in bone marrow stromal cells and MLO-y4 osteocytes
treated with dexametasone with or without risedronate.
Our results in bone marrow stromal cells (Figure 3b)
showed that Ris reduces the negative effect on viability
induced by dexametasone in a dose dependent manner.
In addition, we observed similar results in the MLO-y4
osteocytes (Figure 4). Also in MLO-y4, the addition of
NS-398 reduced the cell viability increased by Ris. This
effect was significant at the highest concentration of Ris
(Figure 4).
Effects of risedronate on gene expression
RT Real Time PCR analysis was carried out to assess the
expression of COX-2 and bone marker Alkaline Phos-
phatase (b-ALP) genes in bone marrow stromal cells
and MLO-y4 osteocytes. In bone marrow stromal cells,
after 72 h of Ris treatment, the expression of genes cod-
ing for COX-2 and b-ALP were upregulated in a dose
dependent manner (Figure 5a, c). To test the effect of
COX-2 in terms of response to Ris treatment, the cul-
tures were treated with or without the NS-398. We
observed a significant decrease in b-ALP gene expression
(and obviously in COX-2 gene expression) in cells
Table 1 Histomorphometric results in rats treated with glucocorticoids (GC) and risedronate (Ris)
Controls Ris GC GC+Ris
Bone volume/tissue volume (%) 35 ± 1 39 ± 1(b,c) 31 ± 1(b) 36 ± 1(a)
Trabecular thickness (μm) 50 ± 1 55 ± 1(b) 43 ± 1(b) 53 ± 1(a)
Trabecular number (N/mm) 3.4 ± 0.2 4.6 ± 0.1(b) 2.9 ± 0.1(b) 4.4 ± 0.1(a,b)
Trabecular separation (μm) 155 ± 6.5 139 ± 4.8(b,c) 273 ± 5.3(b) 144 ± 6.1(a)
Mineral apposition rate (μm/day) 0.66 ± 0.04 0.65 ± 0.04 0.62 ± 0.05(b) 0.65 ± 0.04
Mineralized surface/BS (%) 11.2 ± 1.5 9.8 ± 0.9(b) 9.6 ± 0.9(b) 9.8 ± 1.0(b)
Bone formation rate/BS (μm3/μm2/day 7.4 ± 1.2 6.3 ± 0.6(b) 5.9 ± 0.6(b) 6.3 ± 0.6(b)
Wall thickness (μm) 16.8 ± 1.3 24.9 ± 3.6(b) 12.0 ± 3.1(b) 22.8 ± 5.9(a,b)
Activation frequency (N/yr) 1.6 ± 0.3 0.9 ± 0.2(b) 1.9 ± 0.6 1.0 ± 0.3(a,b)
Active formation period (days) 25.4 ± 2.0 38.8 ± 5.4(b) 19.4 ± 4.8 35.3 ± 9.3(a,b)
Eroded surface/BS (%) 1.9 ± 1.0 1.7 ± 0.7 2.2 ± 1.1 1.9 ± 1.1
BS, bone surface.
a) P < 0.001 vs GC. b) P < 0.05/P < 0.001 vs controls. c) P < 0.001 vs GC + Ris.
All values are expressed as mean ± SD.
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treated with NS-398, confirming a reduced recruitment
of stromal cells to osteoblastic lineage.
In addition, we evaluated the effect of glucocorticoid
on COX-2 expression in response to Ris. We found that
Ris reduced the downregulation due to DEX in a dose
dependent manner (Figure 5b). The same results we
obtained in MLO-y4 osteocytes, after 72 h of Ris treat-
ment (Figure 6a, b). The addition of NS-398 inhibitor
decreased significantly the Ris-induced COX2 and
b-ALP gene overexpression.
Discussion
Clinical trials highlighted that patients with postmeno-
pausal osteoporosis treated long term with bisphospho-
nates show a continuous increase of bone density, an
effect that might not be explained simply by the con-
traction of the remodeling space expected from the inhi-
bition of bone resorption [6,38-40].
Our histomorphometric data show that the main
effect of Ris on remodeling in glucocorticoid-induced
osteoporosis is the prolonged lifespan of osteocytes,
characterized by reduced Bone Formation Rate, activa-
tion frequency and prolonged active Formation Period
associated with increased wall thickness, according to
our previous results [16]. The inhibition of remodelling
along with the increase of wall thickness supported the
hypothesis of a direct effect of Ris on osteoblastic
lineage.
Nevertheless, the active Formation Period is not a
direct measurement of osteoblast lifespan and the
Figure 1 Osteocyte apoptosis (TUNEL) in rats treated with risedronate (Ris) and glucocorticoids (GC). TUNEL positive apoptotic cells with
respect to total cells expressed as percentage were quantified in randomly selected six microscopic fields (200 μm square, each) under 40 ×
magnification. * P < 0.001 vs GC; # P < 0.001 vs GC +Ris.
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increase observed could be due to a prolonged osteo-
blast precursor recruitment to individual bone remodel-
ing units, resulting in a greater total number of
osteoblasts, with no alteration to individual cellular life-
span. Thus, in this study we evaluated also osteocytic
apoptosis to confirm a direct action of Ris in prolonging
cell lifespan. We found that Ris prevents osteocyte
apoptosis in GC-treated rats, according to previous find-
ings by Plotkin et al. [12]. Even if the result confirms a
positive effect of Ris on cell lifespan, this effect can not
completely explain our histomorphometric data that
showed an increased wall thickness, the end product of
osteoblastic activity, also with respect to controls.
Accordingly, it has been suggested that bisphosphonate
action on bone formation may contribute to the continu-
ous positive balance leading to a more complete minerali-
zation of bone tissue that was highlighted also in some
clinical studies [1,6,36,38]. It is still unclear how bispho-
sphonates could stimulate directly bone formation, even if
many metabolic pathways have been suggested: the stimu-
lation of b-FGF [10] and of Bone Morphogenetic Protein
-2 (BMP-2) [17], the upregulation of a cascade of osteo-
blast-related genes including BMP-2, cbfa-1, type 1 col-
lagen and Bone Sialo-Proteins (BSP) [18], the influence on
OPG/RANKL system [2]. In addition, earlier co-culture
studies have shown that the presence of osteoblastic
Figure 2 COX-2 expression in osteocytes of treated rats. COX-2 positive osteocytes in rats treated with risedronate (Ris) and
glucocorticoids (GC). Results were expressed as Immuno-Hystochemical Score, IHS), based on German Immunoreactive. * P < 0.001 vs controls;
# P < 0.001 vs GC; § P < 0.001 vs GC+Ris.
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lineage cells is required also for a complete anti-resorptive
effect of bisphosphonates, suggesting that these drugs inhi-
bit osteoclast activity both directly, interfering with meva-
lonate pathway, but also indirectly trough osteoblast
activation [1,41]. All these findings strengthen the concept
that osteoblastic lineage is another important target of
aminobisphosphonates.
Among all these different mechanisms of osteoblast
activation, it is known that COX-2 and endogenous
prostaglandins regulate bone formation and osteoblast
differentiation in bone marrow stem cells (BMSCs)
[42-44]. On the contrary, COX-2 disruption in BMSC
cultures decreased osteoblastogenesis, and general cell
growth and inhibit or delay fracture healing [45-47].
Since COX-2 are also involved in the early stage of
bone marrow stem cell differentiation toward osteoblas-
tic lineage [42], we may suppose that bisphosphonates
influence osteoblastic lineage also by promoting
osteoblast differentiation and viability at least in part
through COX-2 pathway. This hypothesis is in agree-
ment with recent data that confirm COX-2 as an impor-
tant target of drugs used in metabolic bone diseases,
such us strontium ranelate [30].
On the other hand, administration of a drug that inhi-
bits COX-2 activity, such as non steroidal anti-inflam-
matory drugs (NSAIDs), seems to be associated with an
inhibition of fracture healing and reduction of bone
mineral density [29], even if it is unlikely that NSAIDs
are able to block continuously all PG activity at the
local level in vivo, since PGs work in an autocrine/para-
crine manner and NSAIDs are generally given for short
periods.
According to these findings, our results show an
increased expression of COX-2 in rat osteocytes treated
with Ris and suggest that this pathway could be involved
in the modulation of bone metabolism induced by
Figure 3 Viability values in bone marrow stromal cells. Difference of viability (XTT test) with respect to controls expressed in percentage in
bone marrow stromal cells treated with risedronate (Ris) at different concentrations, with or without NS-398 COX-2 inhibitor (a) and with
dexametasone 1 μM (DEX) (b) with or without risedronate (Ris) at different concentrations. The experiments were performed in triplicate.
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aminobisphosphonates. As already mentioned, we found
that Ris treatment prolongs osteocyte lifespan, reducing
their apoptosis induced by GC. Considering that COX-2
expression and PGs increase have been associated with
higher resistance to apoptosis and tumour promotion in
tissues other than bone [47], the reduced apoptosis and
the higher expression of COX-2 could be strictly linked.
Moreover, Ris could have a potent influence on osteo-
blast precursors. This is a very intriguing aspect that
suggests a positive effect of bisphosphonates both on
the lifespan of osteoblastic lineage and on the recruit-
ment of new cells inducing osteogenic differentiation of
mesenchimal precursors. To confirm this hypothesis, we
evaluated the effect of Ris at different concentrations on
COX-2 as well as on b-ALP gene expression in vitro.
Alkaline phosphatase (ALP), a glycoprotein attached
to the outer cell membrane by a glycosylphosphatidyli-
nositol (GPI) anchor [48], exists as several isoenzymes
and many isoforms present in tissues and serum. The
ALP gene at locus 2q34eq37 encodes the human intest-
inal isoenzyme of ALP whereas at locus 1p36ep34
encodes the human tissue-nonspecific ALP isoforms
derived from bone, liver, and kidney [49]. In this study,
we analyzed the RNA expression related to locus
1p36ep34, so in the bone marrow environment our
results are referred specifically to osteogenic lineage.
This aspect is very important because, in this context,
b-ALP may be considered a specific differentiation mar-
ker of osteoblastic precursors. The concomitant
increased expression of COX-2 and b-ALP genes after
treatment with Ris suggests a direct effect on osteogenic
differentiation of mesenchymal precursors. This direct
effect on osteoblastic lineage has been recently sug-
gested also in another study in vitro, in which zoledro-
nate induced sustained commitment of bone marrow
derived mesenchymal stem cells for osteogenic differen-
tiation [8]. To confirm the direct relationship between
COX-2 increase and osteoblastic activity, we co-treated
cells with a specific COX-2 inhibitor (NS-398), able to
decrease the mRNA COX-2 level [50], obtaining a con-
comitant significant decrease of b-ALP and COX-2 gene
expression. However, the decreased bALP expression
induced by NS-398 could be due also to the decreased
viability of bALP-expressing cells, in addition to the
effect on reduced osteogenic differentiation of mesench-
ymal precursors.
In addition, we evaluated Ris effects on osteocyte cells
in vitro, and we observed similar results obtained on
osteoblasts. This implies that, in addition to an
increased osteogenic recruitment, Ris is able to prolong
the lifespan of osteogenic lineage mature cells. Also in
this case, COX2 gene was involved as suggested by b-
ALP gene expression level in cells treated with Ris alone
or in combination with NS-398 inhibitor. The ability of
Ris to prevent negative GC effects observed on osteo-
genic precursors was confirmed also in MLO-Y4 osteo-
cyte cells in agreement with our results in vivo.
These findings are of clinical relevance because they
suggest a new mechanism through which bisphospho-
nates could exert their anabolic action on bone. The
final result is a positive balance in bone turnover, char-
acterized by an increased number of active osteoblastic/
osteocytic cells that have an important relevance in pre-
sence of bone diseases affecting osteoblastic lineage
such as glucocorticoid-induced osteoporosis. In addition,
this is the first study showing a direct effect of Ris on
osteocytes through the upregulation of COX-2 gene
expression.
Conclusions
In this study, we confirmed that osteocytes could be sti-
mulated by aminobisphosphonates. Considering the role
of osteocytes in maintaining the bone matrix network
and in regulating bone metabolism for correct bone
homeostasis, the effect of aminobisphosphonates on
these cells is very interesting. However, further studies
are needed to elucidate the effective action of drugs on
these cells.
Moreover, COX-2 expression is significantly increased
in osteocytes and in bone marrow cells after Ris treat-
ment. These results suggest COX-2 as an important tar-
get of Ris and support the hypothesis that
aminobisphosphonates may have an anabolic effect on
bone by increasing both the lifespan and the number of
active osteogenic cells.
Figure 4 Viability values in MLO-y4 osteocyte cell line .
Difference of viability (XTT test) expressed in percentage in MLO-y4
osteocytes treated with dexametasone 1 μM (DEX), with or without
risedronate (Ris) at different concentrations. In the right side of the
figure are also reported the effects on viability of risedronate (Ris) at
different concentrations with or without NS-398 COX-2 inhibitor.
The addition of NS-398 limited cell viability increased by Ris. This
effect was significant at the highest concentration of Ris. The
experiments were performed in triplicate.
Valenti et al. Arthritis Research & Therapy 2010, 12:R163
http://arthritis-research.com/content/12/4/R163
Page 9 of 13
Figure 5 COX-2 and b-ALP gene expression in treated bone stromal cells. (a) COX-2 gene expression of bone marrow stromal cells treated
with risedronate (Ris) at different concentrations (0.1 to 10 μM) in presence or absence of NS-398 COX-2 inhibitor. Note that Ris induces
significant COX-2 expression in a dose dependent manner. (b) COX-2 gene expression of bone marrow stromal cells treated with risedronate (Ris)
at different concentrations (0.1 to 10 μM) in presence of dexametasone 1 μM (DEX). (c) bALP gene expression of bone marrow stromal cells
treated with risedronate (Ris) at different concentrations in presence or absence of NS-398 COX-2 inhibitor. The experiments were performed in
triplicate.
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